Tilray (NASDAQ:TLRY) has been assigned a $25.00 target price by equities researchers at Jefferies Financial Group in a report issued on Friday, TipRanks reports. The brokerage currently has a “hold” rating on the stock. Jefferies Financial Group’s price target would suggest a potential upside of 8.41% from the stock’s previous close.
A number of other research firms also recently commented on TLRY. ValuEngine raised shares of Tilray from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd. Zacks Investment Research raised shares of Tilray from a “sell” rating to a “hold” rating in a research report on Friday. Consumer Edge began coverage on shares of Tilray in a research report on Friday, June 28th. They set an “overweight” rating and a $54.00 target price on the stock. Northland Securities reissued a “hold” rating on shares of Tilray in a research report on Wednesday, August 14th. Finally, Benchmark cut their target price on shares of Tilray from $200.00 to $80.00 and set a “buy” rating on the stock in a research report on Wednesday, August 14th. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and five have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $49.06.
TLRY stock traded down $0.61 during trading on Friday, hitting $23.06. The company had a trading volume of 121,940 shares, compared to its average volume of 1,422,791. The firm has a market capitalization of $2.38 billion, a P/E ratio of -28.12 and a beta of 4.44. Tilray has a 52-week low of $20.20 and a 52-week high of $142.84. The company has a 50 day simple moving average of $26.17 and a 200-day simple moving average of $38.98. The company has a quick ratio of 1.61, a current ratio of 2.04 and a debt-to-equity ratio of 1.21.
Tilray (NASDAQ:TLRY) last posted its earnings results on Tuesday, August 13th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.09). The business had revenue of $45.90 million for the quarter, compared to analysts’ expectations of $40.25 million. Tilray had a negative net margin of 121.73% and a negative return on equity of 37.64%. The company’s revenue for the quarter was up 373.2% on a year-over-year basis. During the same period last year, the business posted ($0.17) EPS. Sell-side analysts forecast that Tilray will post -1.15 earnings per share for the current year.
Several large investors have recently added to or reduced their stakes in the company. ETF Managers Group LLC bought a new stake in shares of Tilray in the 2nd quarter valued at about $92,004,000. Morgan Stanley boosted its holdings in shares of Tilray by 44.2% in the 2nd quarter. Morgan Stanley now owns 330,527 shares of the company’s stock valued at $15,390,000 after buying an additional 101,375 shares in the last quarter. Think Investments LP bought a new stake in shares of Tilray in the 2nd quarter valued at about $7,031,000. Vanguard Group Inc. bought a new stake in shares of Tilray in the 2nd quarter valued at about $3,484,000. Finally, Stelac Advisory Services LLC bought a new stake in shares of Tilray in the 2nd quarter valued at about $3,000,000. Institutional investors and hedge funds own 7.62% of the company’s stock.
Tilray Company Profile
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Featured Story: Does the Dogs of the Dow strategy work?
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.